+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Oncology Partnering 2017-2022: Deal Trends, Players and Financials

  • PDF Icon

    Report

  • 2600 Pages
  • June 2022
  • Region: Global
  • CurrentPartnering
  • ID: 2067195
The Global Oncology Partnering 2017-2022: Deal trends, players and financials report provides an understanding and access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies.
  • Trends in Oncology partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Oncology partnering agreement structure
  • Oncology partnering contract documents
  • Top Oncology deals by value
  • Most active Oncology dealmakers

The report provides a detailed understanding and analysis of how and why companies enter oncology partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors oncology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest oncology agreements announced in the healthcare sector.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Oncology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Oncology deals.

The report presents financial deal terms values for Oncology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Oncology dealmaking trends.

  • Chapter 1 provides an introduction to the report.
  • Chapter 2 provides an overview of the trends in Oncology dealmaking since 2017 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
  • Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
  • Chapter 4 provides a review of the leading Oncology deals since 2017. Deals are listed by headline value. The chapter includes the top 25 most active Oncology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
  • Chapter 5 provides comprehensive access to Oncology deals since 2017 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
  • Chapter 6 provides a comprehensive directory of all Oncology partnering deals by specific Oncology target announced since 2017. The chapter is organized by specific Oncology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Oncology partnering deals signed and announced since 2017. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Oncology partnering and dealmaking since 2017.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Oncology technologies and products.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all oncology partnering deals announced since 2017 including financial terms where available including over 5,000 links to online deal records of actual oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Report scope


Global Oncology Partnering 2017-2022: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to oncology trends and structure of deals entered into by leading companies worldwide.

Global Oncology Partnering 2017-2022: Deal trends, players and financials includes:

  • Trends in oncology dealmaking in the biopharma industry since 2017
  • Access to headline, upfront, milestone and royalty data
  • Access to over 5,000 oncology deal records
  • The leading oncology deals by value since 2017

The report includes deals for the following indications: Oral mucositis, Cancer pain, Bone, Neuropathic, Muscular, Lymphoedema, Alopecia, Cachexia, Ulcers, Dysphagia, Tiredness, Weight loss, Nausea, Vomiting, Chemotherapy, Radiotherapy, Adenocarcinoma, Basal cell carcinoma, Bile duct cancer, Bladder cancer, Bone cancer, Brain cancer, Breast cancer, Cervical cancer, Colorectal cancer, Endometrial, Esophageal cancer, Gastric cancer, Head and neck cancer, Kaposi's sarcoma, Kidney cancer, Leukemia, Acute lymphoblastic leukemia, Acute myelogenous leukemia, Chronic lymphocytic leukemia, Chronic myelogenous leukemia, Liver cancer, Lung cancer, Small cell lung cancer, Non small cell lung cancer, Lymphoma, Hodgkin's lymphoma, Non Hodgkin's lymphoma, Melanoma, Mesothelioma, Metastases, Bone metastases, Multiple myeloma, Neuroblastoma, Non-melanoma skin cancer, Ovarian cancer, Pancreatic cancer, Prostate cancer, Renal cell carcinoma, Sarcoma, Solid tumors, Testicular cancer, Thyroid cancer, plus other oncology indicatons.

In Global Oncology Partnering 2017-2022: Deal trends, players and financials, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Oncology Partnering 2017-2022: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 5,000 oncology deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in Oncology dealmaking
2.1. Introduction
2.2. Oncology partnering over the years
2.3. Oncology partnering by deal type
2.4. Oncology partnering by industry sector
2.5. Oncology partnering by stage of development
2.6. Oncology partnering by technology type
2.7. Oncology partnering by therapeutic indication
Chapter 3 -Financial deal terms for Oncology partnering
3.1. Introduction
3.2. Disclosed financials terms for Oncology partnering
3.3. Oncology partnering headline values
3.4. Oncology deal upfront payments
3.5. Oncology deal milestone payments
3.6. Oncology royalty rates
Chapter 4 - Leading Oncology deals and dealmakers
4.1. Introduction
4.2. Most active in Oncology partnering
4.3. List of most active dealmakers in Oncology
4.4. Top Oncology deals by value
Chapter 5 - Oncology contract document directory
5.1. Introduction
5.2. Oncology partnering deals where contract document available
Chapter 6 - Oncology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Oncology therapeutic target
Appendices
Appendix 1 - Directory of Oncology deals by company A-Z since 2017
Appendix 2 - Directory of Oncology deals by deal type since 2017
Appendix 3 - Directory of Oncology deals by stage of development since 2017
Appendix 4 - Directory of Oncology deals by technology type since 2017
Further reading on dealmaking
Deal type definitions
Table of figures
Figure 1: Oncology partnering since 2017
Figure 2: Oncology partnering by deal type since 2017
Figure 3: Oncology partnering by industry sector since 2017
Figure 4: Oncology partnering by stage of development since 2017
Figure 5: Oncology partnering by technology type since 2017
Figure 6: Oncology partnering by indication since 2017
Figure 7: Oncology deals with a headline value
Figure 8: Oncology deals with upfront payment values
Figure 9: Oncology deals with milestone payment
Figure 10: Oncology deals with royalty rates
Figure 11: Active Oncology dealmaking activity since 2017
Figure 12: Top Oncology deals by value since 2017

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 1ST Biotherapeutics
  • 2bPrecise
  • 2cureX
  • 2seventy bio
  • 2X Oncology
  • 3B Pharmaceuticals
  • 3D Medicines
  • 3P Biopharmaceuticals
  • 3SBio
  • 4baseCare
  • 4C Biomed
  • 4D Path
  • 4D Pharma
  • 5AM Ventures
  • 7 Hills Pharma
  • 9 Meters Biopharma
  • 48Hour Discovery
  • 111
  • 1717 Life Science Ventures
  • A*STAR Bioinformatics Institute
  • A*STAR Singapore Immunology Network
  • A*STAR’ Institute of Molecular and Cell Biology
  • A-Alpha Bio
  • A2 Biotherapeutics
  • A2A Pharmaceuticals
  • Aadi Bioscience
  • Aarvik Therapeutics
  • Abbisko Therapeutics
  • Abbvie
  • Abcam
  • AbCellera
  • Abcuro
  • Abdul Latif Jameel Health
  • Abexxa Biologics
  • Abilita Bio
  • Abingworth Management
  • Abintus Bio
  • Ablaze Pharmaceuticals
  • ABL Bio
  • Ab Magnitude Ventures
  • Abound Bio
  • Abpro
  • Abramson Cancer Center
  • AbSci
  • ABVC BioPharma
  • Abveris
  • ABX
  • Abzena
  • Academia Sinica
  • Academic and Community Cancer Research United
  • AC Bioscience
  • Accelerate Brain Cancer Cure
  • Accent Therapeutics
  • Accenture
  • Access to Comprehensive Genomic Profiling Coalition
  • Accord Healthcare
  • Accudata Systems
  • Accuray
  • ACEA Biosciences
  • ACEA Therapeutics
  • Acentrus Specialty
  • Acepodia
  • Acerand Therapeutics
  • Acerta Pharma
  • Aceso Life Science
  • Achilles Therapeutics
  • Acibadem University
  • Acino Pharma
  • Acoustic MedSystems
  • Acrivon Therapeutics
  • Acrotech Biopharma
  • Actelion
  • ACT Genomics
  • Actimed Therapeutics
  • Actinium Pharmaceuticals
  • Actuate Therapeutics
  • Actym Therapeutics
  • Acucela
  • Acuitas Therapeutics
  • Acuity Pharmaceuticals
  • Acupath Laboratories
  • Adagene
  • AdAlta
  • Adamis Pharmaceuticals
  • Adaptate Biotherapeutics
  • Adaptiiv
  • Adaptimmune
  • Adaptive Biotechnologies
  • AdaptVac
  • ADC Therapeutics
  • Addario Lung Cancer Medical Institute
  • Adgero Biopharmaceuticals
  • Adicet Bio
  • ADIENNE Pharma & Biotech
  • Adimab
  • Adium Pharma
  • Adlai Nortye
  • AdoRx Therapeutics
  • ADT Pharmaceuticals
  • Adult Brain Tumor Consortium
  • Aduro BioTech
  • Advaite
  • AdvaMed
  • Advanced Accelerator Applications
  • Advanced BioScience Laboratories
  • Advanced Dermatology and Cosmetic Surgery Group
  • Advanced Nuclear Medicine Ingredients
  • Advanced Proteome Therapeutics
  • Advanced Radiation Therapy
  • Advanz Pharma
  • Advaxis
  • Aeglea BioTherapeutics
  • Aerpio Pharmaceuticals
  • Aethlon Medical
  • Aetion
  • Aetna
  • AffaMed Therapeutics
  • Affigen
  • Affimed Therapeutics
  • Affinia Therapeutics
  • Again Life Italia
  • Agalimmune
  • AGC Biologics
  • Agena Bioscience
  • Agencja Badan Medycznych
  • Agendia
  • Agenus Bio
  • AgeX Therapeutics
  • Agilent Technologies
  • Agilvax
  • Agios Pharmaceuticals
  • AG Mednet
  • AgonOx
  • AiCure
  • Aidence
  • Aidoc
  • Aiforia Technologies
  • AIkido Pharma
  • Aileron Therapeutics
  • AimedBio
  • AIMM Therapeutics
  • Aion Therapeutic
  • AirXpanders
  • Ajax Therapeutics
  • Ajinomoto
  • Akeso Biopharma
  • Akoya Biosciences
  • Akrevia Therapeutics
  • AKSO Biopharmaceutical
  • Albany Medical College
  • Albert Einstein College of Medicine
  • Alcami
  • Alcedis
  • Alchemab
  • Aldevron
  • Alector
  • Aleta Biotherapeutics
  • Alex’s Lemonade Stand Foundation
  • Alibaba Health
  • Alkermes

Methodology

  • The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
  • The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
  • The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
  • The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
  • The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

The publisher provides comprehensive coverage of the following partnering or deal types:

  • Asset purchase
  • Assignment
  • Co-development
  • Co-market
  • Co-promotion
  • Collaborative R&D
  • Contract service
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Royalty financing
  • Settlement
  • Spin out
  • Sub license
  • Supply
  • Termination
  • Warrant

Every deal record is fully categorized and includes the following data, where available:

  • Industry sector
  • Therapy areas
  • Technology type
  • Deal components
  • Financial terms
  • Stage of development
  • Exclusivity
  • Asset type
  • Geographic focus
  • Excluded geography
  • Company press release
  • SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

 

 

Loading
LOADING...